RxDoctor Payments Data

Marc Odrich, MD

Ophthalmology · Charlottesville, VANPI 1174675631

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $471,699 of the $496,968 with a category attached, or 94.9%. Johnson & Johnson Surgical Vision, Inc. accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $256,589 and has fallen 97.3% since, to $6,847 in 2024. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$496,968in general payments, 2019–2025

Across 159 payments — averaging $3125.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$497K
  • Glaukos Corporation$100

What the payments were for

  • Consulting fees$471,69995%
  • Travel & lodging$23,8745%
  • Food & beverage$1,3950%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$496,968 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$43,654
Medicare patients
178
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast25$17,775
RestasisCyclosporine18$11,514
Fluorometholone27$1,733
ErythromycinErythromycin Base134$1,304
Doxycycline Hyclate47$496
Brimonidine Tartrate24$397
Timolol Maleate11$53
Azithromycin11$32

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →